Mirum Pharmaceuticals, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 08D.F | IONS | TVTX | RARE | ARWR | BMRN | |
|---|---|---|---|---|---|---|
| Market cap | 5.52B | 6.67B | 5.03B | 1.75B | 8.71B | 11.07B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -25.5 | -35.0 | 9.9 | 76.1 | -12.4 | 9.0 |
| Price/book | 15.7 | 15.1 | 222.1 | -5.8 | 18.7 | 1.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +28.38% | −45.82% | +57.42% | −44.56% | +55.68% | +10.20% |
| Today | +0.90% | −0.67% | +6.09% | +3.19% | +3.56% | +2.64% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 08D.F news ›Mirum Pharmaceuticals Announces Positive Results from Cohort 2 of the Pivotal PROGRESS Study of ATEBRIOZ™ (zilurgisertib) in Pediatric Patients Aged 6 to
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), a leading rare disease company, today announced positive results from Cohort 2 of the pivotal PROGRESS study of ATEBRIOZ™ (zilurgisertib), an oral activin receptor-like kinase 2 (ALK2) inhibitor,…
Mirum Pharmaceuticals Reports Significant Reduction in HO Lesion Volume in PROGRESS Cohort 2 FOP Trial
On October 26, 2026, Mirum Pharmaceuticals, Inc. announced positive outcomes from Cohort 2 of its pivotal PROGRESS trial assessing ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to under 12 ... On October 26, 2026, Mirum…
Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) Stock Rated “Moderate Buy” by Sell-Side Brokerages
Posted by Tristan Rich on Oct 26th, 2026 Get Our Latest Report on MIRM Mirum Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing treatments for rare diseases, particularly disorders affecting the…
Mirum Pharmaceuticals (NASDAQ:MIRM) vs. Dyadic International (NASDAQ:DYAI) Head to Head Comparison
Posted by Defense World Staff on Oct 26th, 2026 Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and Dyadic International (NASDAQ:DYAI – Get Free Report) are both healthcare companies, but which is the better business? We will compare…
Critical Survey: Mirum Pharmaceuticals (NASDAQ:MIRM) versus United Therapeutics (NASDAQ:UTHR)
Posted by Sarita Garza on Oct 25th, 2026 Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and United Therapeutics (NASDAQ:UTHR – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two…
Head-To-Head Review: Mirum Pharmaceuticals (NASDAQ:MIRM) & Regeneron Pharmaceuticals (NASDAQ:REGN)
Posted by Kim Johansen on Oct 23rd, 2026 Mirum Pharmaceuticals (NASDAQ:MIRM – Get Free Report) and Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) are both healthcare companies, but which is the superior business? We will compare…
Total non-current liabilities of Mirum Pharmaceuticals, Inc. – FWB:08D
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. Its products pipeline includes Maralixibat,…
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia Transcript
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Phase 3 EXPAND Study Results for Maralixibat in Cholestatic Pruritus Including Biliary Atresia October 12, 2026 8:30 AM EDT Andrew McKibben - Senior Vice President, Strategic Finance & Investor…
Mirum Pharmaceuticals reports LIVMARLI met Phase 3 EXPAND endpoint
The treatment improved itch scores by 0.98 points more than placebo, with a supplemental U.S. drug application planned for the first half of 2027. Mirum Pharmaceuticals, Inc. NASDAQMIRM reported on Monday that LIVMARLI met the primary…
Mirum Pharmaceuticals Announces Primary Endpoint Met in Phase 3 EXPAND Study of LIVMARLI® (maralixibat) in Ultra-Rare Cholestatic Liver Diseases
- Maralixibat demonstrated a statistically significant reduction in cholestatic pruritus compared with placebo (p=0.0004), and a 69% reduction in serum bile acids versus placebo (p - Mirum plans U.S. sNDA submission in the first half of…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- themarketsdaily.com5
- defenseworld.net3
- seekingalpha.com3
- financialcontent.com2
- tradingview.com2
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 17 articles, not a forecast.